581 related articles for article (PubMed ID: 9523730)
1. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
2. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
de Jong S; Zijlstra JG; de Vries EG; Mulder NH
Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus.
McPherson JP; Brown GA; Goldenberg GJ
Cancer Res; 1993 Dec; 53(24):5885-9. PubMed ID: 8261398
[TBL] [Abstract][Full Text] [Related]
5. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
6. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
10. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
11. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
12. Biochemical characterization of cisplatin-resistance in MKN-45 human stomach adenocarcinoma cell line.
Hong WS; Son YS
Anticancer Res; 1996; 16(5A):3031-6. PubMed ID: 8917423
[TBL] [Abstract][Full Text] [Related]
13. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
Engel R; Valkov NI; Gump JL; Hazlehurst L; Dalton WS; Sullivan DM
Exp Cell Res; 2004 May; 295(2):421-31. PubMed ID: 15093741
[TBL] [Abstract][Full Text] [Related]
14. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
15. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
16. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
17. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
19. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
20. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
